Navigation Links
Cyberonics Reports Record Sales and Operating Profit in Fiscal 2010 Second Quarter
Date:11/18/2009

HOUSTON, Nov. 18 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced results for the quarter ended October 23, 2009.

Quarterly highlights

Results for the second quarter of fiscal 2010 compared to the second quarter of fiscal 2009 include:

  • Net sales of $40.7 million, a 13% increase from $36.0 million;
  • Income from operations of $9.1 million, an increase of 101% over the prior year;
  • U.S. and international epilepsy unit sales increased by 6% and 13%, respectively;
  • Net income of $50.1 million;
  • Adjusted non-GAAP net income of $9.1 million compared with an adjusted non-GAAP net income of $3.9 million in the prior year;
  • Adjusted non-GAAP diluted earnings per share of $0.32, an increase of 129% over the prior year;
  • Announcement of several development collaborations.

As discussed below under "Use of Non-GAAP Financial Measures," the company presents non-GAAP financial measures, adjusted non-GAAP net income and adjusted non-GAAP diluted earnings per share, in this release. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP. Please refer to the attached reconciliation between GAAP and non-GAAP financial measures.

Net sales

Worldwide sales for the second quarter of fiscal 2010 were $40.7 million compared to $36.0 million in the comparable period of fiscal 2009, representing an increase of 13%.

U.S. net product sales attributable to the epilepsy indication increased to an estimated $33.2 million, compared with $28.6 million in the comparable period of fiscal 2009, an increase of $4.6 million, or 16%.

International net sales of $6.8 million increased by $0.3 million from the comparable period of fiscal 2009. International epilepsy unit sales increased by 13% in the second quarter of fiscal 2010. The net sales increase was impacted by a higher percentage of sales being made through distributors.

Sales for the six months ended October 23, 2009 were $79.2 million, an increase of $9.5 million, or 14%, when compared to the same period in fiscal 2009.

Gross profit

The gross profit for the second quarter of fiscal 2010 represented 87.4% of net sales compared to 85.6% in the second quarter of fiscal 2009. This increase is primarily a result of higher production volumes and improved manufacturing efficiencies, as well as a higher average selling price due to product mix changes.

Operating expenses

Operating expenses increased by $0.2 million to $26.5 million for the second quarter of fiscal 2010 from the $26.3 million recorded in the comparable period of fiscal 2009 and were materially unchanged from the first quarter of the current fiscal year. Expenses for the quarter ended October 23, 2009 included $2.2 million for stock-based compensation, a decrease of $0.5 million from the comparable period of fiscal 2009.

For the six-month period ended October 23, 2009, operating expenses totaled $53.2 million, an increase of $0.7 million, or 1%, over the same period of fiscal 2009.

Income from operations

The company reported income from operations of $9.1 million during the second quarter of fiscal 2010, compared with income from operations of $4.5 million in the comparable period of fiscal 2009, an increase of over 100%. This quarterly operating profit is the highest ever recorded by the company.

For the six-month period ended October 23, 2009, income from operations totaled $15.6 million, compared to $7.3 million in the same period of fiscal 2009, an increase of 114%.

Debt repurchase / other income

During the recently completed quarter, the company repurchased $7.5 million of its outstanding convertible debt for a total consideration of $6.7 million and recorded a net gain of approximately $0.7 million, including the impact of tax and the accelerated amortization of deferred issuance costs. Convertible debt outstanding as of October 23, 2009 totaled $39.2 million. Subsequent to quarter end, the company repurchased a further $8.3 million of its outstanding convertible debt, for total consideration of $7.6 million, and expects to record a net gain of approximately $0.5 million in its fiscal third quarter.

Income taxes

The company recorded a non-cash tax benefit in the second quarter of fiscal 2010 of $40.5 million resulting from the reversal of its tax valuation allowance related to net operating losses. This benefit represents approximately 40% of the valuation allowance previously recorded against the company's deferred tax asset.

Net income

The company reported net income of $50.1 million, or $1.73 per diluted share, for the second quarter of fiscal 2010, compared with a net income of $8.4 million, or $0.14 cents per diluted share, for the second quarter of fiscal 2009.

For the second quarter of fiscal 2010, the company reported adjusted non-GAAP net income and adjusted non-GAAP diluted earnings per share of $9.1 million and $0.32 cents per share, respectively, compared with $3.9 million and $0.14 cents per share for the second quarter of fiscal 2009.

The number of diluted shares for the quarter and the year to date includes approximately 940,000 shares resulting from the dilutive effect of the remaining convertible notes on an as if converted basis. Although the gain on early extinguishment of the convertible debt is included in the calculation of net income, as per the applicable accounting rules, it is excluded from the calculation of net income per diluted share.

Balance sheet and cash flow

The company generated positive operating cash flow of $16.9 million during the six-month period ended October 23, 2009. Available cash and cash equivalent balances were $60.5 million at quarter end, compared with debt outstanding of $39.2 million.

Results and objectives

"Our performance in fiscal 2010 continues to be robust," commented Dan Moore, Cyberonics' President and Chief Executive Officer. "The company achieved record net sales, record income from operations, and significant cash flow from operations. Our core U.S. epilepsy business continues to reflect solid growth, and our international operations produced a third consecutive quarter of double-digit unit growth, increasing by 13% over the second quarter of the prior year.

"Our stockholders' equity has now reached $87 million. This number was negative as recently as the first quarter of fiscal 2009. We expect to continue producing strong cash flow and with our debt at reasonable levels, the company's balance sheet affords considerable flexibility.

"We estimate that unit sales of replacement generators increased in the second quarter of fiscal 2010 relative to the first quarter of fiscal 2010 and the second quarter of fiscal 2009. We believe that this number is likely to increase over the next two years, and we plan to discuss the basis for this assertion at our previously announced investor day presentation scheduled for December 4, 2009 in Boston.

"We believe that both the U.S. and international epilepsy markets represent significant opportunities for the company to realize consistent growth in both sales and earnings in the coming years," Mr. Moore continued. "Specifically, the Cyberonics team is dedicated to development efforts to improve the efficacy of VNS Therapy(TM) for epilepsy, with particular attention to research efforts around seizure detection and improved stimulation parameters. Again, these efforts will be discussed in greater detail at the investor day presentation.

"With respect to international markets, the Japanese authorities completed a quality audit at our Houston office in the first week of September and a clinical audit in Japan in November."

Mr. Moore concluded, "We are maintaining our longer term goals for our epilepsy business, which include consistent annual unit growth in the range of 10% to 20% and the achievement of an operating margin of 25% by fiscal 2011."

Fiscal 2010 guidance

Based on our first half performance, Cyberonics is increasing its previously provided guidance range for income from operations from $24 million to $27 million to $28 million to $30 million, and increasing its guidance range for net sales from $157 million to $161 million to $159 million to $162 million.

Additional details will be provided during the upcoming conference call and in the accompanying presentation slides, as described below.

Use of Non-GAAP Financial Measures

Management has disclosed financial measurements in this press announcement that present financial information that is not in accordance with Generally Accepted Accounting Principles (GAAP). These measurements are not substitutes for GAAP measurements, although company management uses these measurements as an aid in monitoring the company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against other medical technology companies. Non-GAAP net income and non-GAAP diluted earnings per share measure the income of the company excluding the gain on early extinguishment of the company's convertible debt, which is considered by management to be outside of the normal on-going operations of the company. Non-GAAP net income also measures the income of the company excluding the income tax benefit resulting from the partial reversal of its tax valuation allowance related to net operating losses. Management uses and presents non-GAAP net income and non-GAAP diluted earnings per share because management believes that in order to properly understand the company's short and long-term financial trends, the impact of these unusual items should be eliminated from on-going operating activities. Management also uses non-GAAP net income and non-GAAP diluted earnings per share to forecast and evaluate the operational performance of the company as well as to compare results of current periods to prior periods on a consistent basis.

Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Please refer to the attached reconciliation between GAAP and non-GAAP financial measures.

Fiscal Year 2010 Second Quarter Results Conference Call Instructions

A conference call to discuss fiscal year 2010 second quarter results will be held at 9:00 AM EST on Thursday, November 19, 2009. To listen to the conference call live by telephone dial 877-313-8035 (if dialing from within the U.S.) or 706-679-4838 (if dialing from outside the U.S.). The conference ID is 40115998. Presentation slides will be available on-line at www.cyberonics.com no later than 8:00 AM EST on Thursday, November 19, 2009. A replay of the conference call will be available approximately two hours after the completion of the live call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.). The replay conference ID access code is 40115998. The replay will be available for one week on the above number and subsequently on the Company's website for a period of six months.

About VNS Therapy(TM) and Cyberonics

Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of epilepsy and depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning the company's balance sheet affording considerable flexibility, increasing unit sales of replacement generators over the next two years, consistent growth in both sales and earnings in the coming years in the U.S. and international epilepsy markets, developing technology to improve the efficacy of VNS Therapy(TM) for epilepsy, including devices incorporating seizure detection and improved stimulation parameters, obtaining regulatory approval in Japan, achieving consistent annual unit growth in the range of 10% to 20% and an operating margin of 25% by fiscal 2011, and fiscal 2010 guidance for net sales and income from operations. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy(TM) and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy(TM) for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto or to our stock option grants, procedures, and practices and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 24, 2009, and Quarterly Report on Form 10-Q for the fiscal quarter ended July 23, 2009.


    Contact information
    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main:  (281) 228-7262
    Fax:  (281) 218-9332
    ir@cyberonics.com

                           CYBERONICS, INC. AND SUBSIDIARY
                        CONSOLIDATED STATEMENTS OF OPERATIONS
                                    (Unaudited)

                              For the Thirteen         For the Twenty-Six
                                Weeks Ended               Weeks Ended
                                -----------               -----------
                            October 23, October 24, October 23,  October 24,
                                2009        2008        2009         2008
                                ----        ----        ----         ----


    Net sales               $40,718,172 $36,031,971 $79,219,409  $69,763,829
    Cost of sales             5,117,712   5,177,800  10,457,857    9,994,562
                              ---------   ---------  ----------    ---------
      Gross Profit           35,600,460  30,854,171  68,761,552   59,769,267
                             ----------  ----------  ----------   ----------
    Operating Expenses:
      Selling, general
       and administrative    21,372,020  21,531,424  42,990,911   43,056,191
      Research and
       development            5,145,194   4,806,220  10,175,283    9,414,395
                              ---------   ---------  ----------    ---------
        Total Operating
         Expenses            26,517,214  26,337,644  53,166,194   52,470,586
                             ----------  ----------  ----------   ----------
        Income from
         Operations           9,083,246   4,516,527  15,595,358    7,298,681

    Interest income              23,504     433,646      65,767      941,933
    Interest expense           (430,848)   (929,018)   (933,533)  (2,090,668)
    Gain on early
     extinguishment of debt     672,137   4,612,845   2,196,466    4,612,845
    Other income, net           332,905    (162,494)    825,795     (145,260)
                                -------    --------     -------     --------

    Income before income
     tax                      9,680,944   8,471,506  17,749,853   10,617,531
    Income tax (benefit)
     expense                (40,463,173)    121,304 (40,259,723)     214,528
                            -----------     ------- -----------      -------

        Net income          $50,144,117  $8,350,202 $58,009,576  $10,403,003
                            ===========  ========== ===========  ===========

    Basic income per share        $1.81       $0.31       $2.10        $0.39
    Diluted income per share      $1.73       $0.14       $1.96        $0.23
                                  =====       =====       =====        =====

    Shares used in computing
     basic income per
     share                   27,748,669  26,680,551  27,640,539   26,550,667
    Shares used in computing
     diluted income per
     share                   28,876,518  27,516,723  28,873,183   27,632,656
                             ==========  ==========  ==========   ==========


                        CYBERONICS, INC. AND SUBSIDIARY
                     CONDENSED CONSOLIDATED BALANCE SHEETS
                      (Unaudited except where indicated)



                                October 23, 2009         April 24, 2009
                                ----------------         --------------
                                                           (Audited)
                           ASSETS

    Current Assets
      Cash and cash
       equivalents                $60,498,938             $66,225,479
      Restricted cash               1,000,000               1,000,000
      Accounts receivable,
       net                         24,838,576              22,250,653
      Inventories                  13,830,193              12,841,064
      Deferred tax assets           6,068,009                   9,804
      Other current assets          1,857,438               2,206,902
                                    ---------               ---------
        Total Current Assets      108,093,154             104,533,902
    Property and
     equipment, net and
     other assets                   8,096,628               7,103,390
    Deferred tax assets            34,967,682                 406,336
                                   ----------                 -------
        Total Assets             $151,157,464            $112,043,628
                                 ============            ============


                   LIABILITIES AND STOCKHOLDERS' EQUITY

    Current Liabilities           $17,577,088             $17,645,240
    Long term
     liabilities:
      Convertible notes            39,215,000              62,339,000
      Deferred license
       revenue and other            6,898,404               7,647,544
                                    ---------               ---------
        Total Long Term
         Liabilities               46,113,404              69,986,544
        Total Liabilities          63,690,492              87,631,784
    Total Stockholders'
     Equity                        87,466,972              24,411,844
                                   ----------              ----------
    Total Liabilities and
     Stockholders' Equity        $151,157,464            $112,043,628
                                 ============            ============



                        CYBERONICS, INC. AND SUBSIDIARY
                   CONDENSED CONSOLIDATED STATEMENTS OF CASH
                                      FLOWS
                                  (Unaudited)


                                      For the Twenty-Six Weeks Ended
                                      ------------------------------
                                  October 23, 2009      October 24, 2008
                                  ----------------      ----------------


    Cash Flow From Operating
     Activities:
    Net Income                      $58,009,576           $10,403,003
      Non-Cash items included
       in Net Income
        Gain on early
         extinguishment of debt      (2,196,466)           (4,612,845)
        Stock-base compensation       4,455,545             5,221,077
        Deferred income tax         (40,619,551)                2,626
        Unrealized (gain) loss
         in foreign currency
         transactions                  (719,792)              412,790
        Other                           519,463               819,027
      Changes in Operating
       Assets and Liabilities
        Accounts receivable, net     (1,782,473)           (1,117,839)
        Inventories                  (1,182,686)              405,696
        Other                           429,041              (896,865)
                                        -------              --------
          Net Cash Provided By
           Operating Activities      16,912,657            10,636,670
                                     ----------            ----------
    Cash Flow From Investing
     Activities:
          Net Cash Used in
           Investing Activities      (2,537,564)             (659,361)
                                     ----------              --------
    Cash Flow From Financing
     Activities:
      Repurchase of
       convertible notes            (20,565,400)          (34,902,750)
      Proceeds from exercise
       of options for common
       stock                            597,692             4,256,353
      Purchase of treasury
       stock                            (37,551)             (532,293)
                                        -------              --------
          Net Cash Used in
           Financing Activities     (20,005,259)          (31,178,690)
                                    -----------           -----------

    Effect of Exchange Rate
     Changes on Cash and
     Cash Equivalents                   (96,375)             (516,456)
                                        -------              --------

    Net Decrease in Cash and
     Cash Equivalents                (5,726,541)          (21,717,837)
    Cash and Cash
     Equivalents at
     Beginning of Period             66,225,479            91,058,692
                                     ----------            ----------
    Cash and Cash
     Equivalents at End of
     Period                         $60,498,938           $69,340,855
                                    ===========           ===========



                   RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
                                    (Unaudited)

                             For the Thirteen         For the Twenty-Six
                                Weeks Ended              Weeks Ended
                           October 23,  October 24,  October 23,   October 24,
                              2009        2008          2009          2008
                              ----        ----          ----          ----

    Net income            $50,144,117   $8,350,202   $58,009,576  $10,403,003
                          -----------   ----------   -----------  -----------

    Deduct effect of gain
     on early extinguishment
     of debt                 (636,467)  (4,440,387)   (2,035,462)  (4,081,999)
                             --------   ----------    ----------   ----------

    Deduct effect of
     reduction in valuation
     allowance            (40,450,068)           -   (40,450,068)           -
                          -----------          ---   -----------          ---

    Non-GAAP adjusted net
     income                $9,057,582   $3,909,815   $15,524,046   $6,321,004
                           ==========   ==========   ===========   ==========

    Diluted weighted
     average shares
     outstanding           28,876,518   27,516,723    28,873,183   27,632,656
    Effect of reduction
     of valuation allowance
     on outstanding
     Convertible Notes       (944,940)           -      (944,940)           -
                             --------          ---      --------          ---
    Non-GAAP adjusted
     diluted weighted
     average shares
     outstanding           27,931,578   27,516,723    27,928,243   27,632,656
                           ==========   ==========    ==========   ==========

    Diluted income per share    $1.73        $0.14         $1.96        $0.23
    Non-GAAP adjusted
     diluted income per share   $0.32        $0.14         $0.56        $0.23



SOURCE Cyberonics, Inc.


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Cyberonics Announces Epilepsy Technology Collaborations
2. Cyberonics to Present at Maxim Group Growth Conference
3. Cyberonics to Present at UBS Global Life Sciences Conference
4. Cyberonics Reports Strong Fiscal 2010 First Quarter Results
5. Cyberonics to Present at Canaccord Adams 29th Annual Global Growth Conference
6. Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results
7. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
8. Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
9. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
10. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
11. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... ... ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has published ... Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. (After ... up exactly with Bible Prophecy – a protected way for those who will believe. ...
(Date:12/2/2016)... ... December 02, 2016 , ... On ... individuals and families from eight different sites throughout Miami-Dade and Broward counties. This ... volunteers worked very hard on Thanksgiving morning by putting together individual meals via ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... National Pharmacy Services, LLC ("Maxor"), today announced that it has ... of Texas -based Maxor Specialty / IV ... both company,s clinical expertise and high-touch patient service models to ... About Maxor ... , , Established ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific Corporation ... agreement to acquire certain manufacturing assets and capabilities of ... NVC) advanced biological tissue business, as well as a ... $75 million in cash. The Neovasc advanced biological tissue ... the Boston Scientific Lotus™ Valve System. * Upon ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology: